Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTXR 
Citius Pharmaceuticals Inc (CTXR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CTXR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.6% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.90M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.35 | 52 Weeks Range 0.65 - 15.25 | Updated Date 09/17/2025 |
52 Weeks Range 0.65 - 15.25 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.88% | Return on Equity (TTM) -54.7% |
Valuation
Trailing PE - | Forward PE 1.81 | Enterprise Value 15696788 | Price to Sales(TTM) - |
Enterprise Value 15696788 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.74 | Shares Outstanding 17012200 | Shares Floating 16257870 |
Shares Outstanding 17012200 | Shares Floating 16257870 | ||
Percent Insiders 2.9 | Percent Institutions 5.46 |
Upturn AI SWOT
Citius Pharmaceuticals Inc
Company Overview
History and Background
Citius Pharmaceuticals, Inc. was founded in 2014. It is a late-stage biopharmaceutical company focused on developing and commercializing critical care products, with a focus on anti-infectives in adjunct cancer care, unique anti-cancer agents, and stem cell therapy. The company's evolution has centered on advancing its pipeline of drug candidates through clinical trials.
Core Business Areas
- Mino-Lok: An antibiotic lock solution used to treat catheter-related bloodstream infections (CRBSIs). It is designed to salvage central venous catheters (CVCs), reducing the need for removal and replacement.
- Halo-Lido: A topical formulation of halobetasol propionate and lidocaine to treat hemorrhoids.
- CITI-002 (iMSC): Mesenchymal stem cell therapy for Acute Respiratory Distress Syndrome (ARDS).
Leadership and Structure
Leonard Mazur is the Chairman and CEO. Myron Holubiak is the President. The company has a board of directors and a management team responsible for overseeing its clinical development programs and commercialization strategies.
Top Products and Market Share
Key Offerings
- Mino-Lok: Mino-Lok aims to reduce catheter-related bloodstream infections. Phase 3 trial completed, NDA resubmitted in April 2024. Competitors include currently used antibiotic lock therapies and catheter removal, though Mino-Lok aims for catheter salvage benefit. No current market share data available as product is awaiting approval.
- Halo-Lido: Aims to treat hemorrhoids. Currently in Phase 2b trial. Competitors include Anucort HC, Preparation H and other local anesthetics and corticosteroids. No current market share data available as product is not yet approved.
Market Dynamics
Industry Overview
Citius operates in the biopharmaceutical industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Focus areas include anti-infectives, cancer care, and regenerative medicine, each with specific market dynamics.
Positioning
Citius positions itself as a company focused on developing innovative therapies for unmet medical needs in critical care and cancer. Their competitive advantage lies in potentially reducing treatment costs and offering novel solutions like catheter salvage and ARDS treatment.
Total Addressable Market (TAM)
The TAM for CRBSI treatment is estimated to be in the hundreds of millions of dollars annually. For hemorrhoid treatment, it is also substantial. Citius aims to capture a significant portion of these markets with Mino-Lok and Halo-Lido, respectively. ARDS market is also significant.
Upturn SWOT Analysis
Strengths
- Late-stage pipeline (Mino-Lok NDA resubmitted)
- Targeting unmet medical needs
- Experienced management team
- Focus on cost-effective therapies
Weaknesses
- Reliance on regulatory approvals
- Limited product portfolio
- History of financial losses
- Small company relative to larger pharma players
Opportunities
- Potential FDA approval of Mino-Lok
- Expansion of pipeline through acquisitions or licensing
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for other pipeline candidates
Threats
- Regulatory setbacks (e.g., FDA rejection)
- Competition from existing treatments
- Failure of clinical trials
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- MLND
- BSX
- XBI
Competitive Landscape
Citius is a small player compared to larger pharmaceutical companies. Its competitive advantage lies in potentially offering more cost-effective and innovative solutions for unmet medical needs. Market Share for CTXR is 0 because no products have been approved yet.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by advancing clinical trials and securing funding.
Future Projections: Future growth hinges on FDA approval of Mino-Lok and successful development of other pipeline candidates. Analyst estimates vary widely based on regulatory and clinical milestones.
Recent Initiatives: Resubmission of the Mino-Lok NDA and progression of Halo-Lido into Phase 2b trials are key initiatives.
Summary
Citius Pharmaceuticals is a clinical-stage company with a focus on unmet medical needs, particularly in anti-infectives and cancer care. The company's success hinges on obtaining regulatory approval for its lead candidate, Mino-Lok, and advancing its other pipeline programs. Financial losses are a concern, but potential market opportunities are significant. Further clinical trial successes and strategic partnerships are critical for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Citius Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Company Press Releases
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Data may be outdated and may not be 100% accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Citius Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cranford, NJ, United States | ||
IPO Launch date 2017-07-06 | Co-Founder, CEO, Chairman & Secretary Mr. Leonard L. Mazur | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://citiuspharma.com |
Full time employees 23 | Website https://citiuspharma.com | ||
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.